Edition:
United States

Arrowhead Pharmaceuticals Inc (ARWR.OQ)

ARWR.OQ on NASDAQ Stock Exchange Global Select Market

1.75USD
3:59pm EST
Change (% chg)

$0.02 (+1.16%)
Prev Close
$1.73
Open
$1.73
Day's High
$1.75
Day's Low
$1.70
Volume
90,246
Avg. Vol
330,773
52-wk High
$8.22
52-wk Low
$1.20

ARWR.OQ

Chart for ARWR.OQ

About

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of... (more)

Overall

Beta: 2.06
Market Cap(Mil.): $128.32
Shares Outstanding(Mil.): 74.17
Dividend: --
Yield (%): --

Financials

  ARWR.OQ Industry Sector
P/E (TTM): -- 44.03 29.85
EPS (TTM): -1.34 -- --
ROI: -74.29 -1.39 14.85
ROE: -79.44 -1.05 16.28

BRIEF-Silence Therapeutics Plc reports 9.21 percent stake in Arrowhead Pharmaceuticals Inc as of Jan 3 - SEC filing

* Silence Therapeutics Plc reports 9.21 percent stake in Arrowhead Pharmaceuticals Inc as of Jan 3 - SEC filing

Jan 13 2017

BRIEF-Arrowhead provides response to new minority shareholder announcement

* Arrowhead provides response to new minority shareholder announcement

Jan 09 2017

Arrowhead Pharma sinks after shelving three drug programs

Shares of Arrowhead Pharmaceuticals Inc sank more than 60 percent in premarket trading on Wednesday, a day after the company said it would stop developing all drugs being tested on humans due to a setback in its drug-delivery technology.

Nov 30 2016

BRIEF-Arrowhead Pharmaceuticals focuses resources on subcutaneous and extra-hepatic RNAi Therapeutics

* Arrowhead Pharmaceuticals focuses resources on subcutaneous and extra-hepatic RNAi Therapeutics

Nov 29 2016

BRIEF-Arrowhead Pharmaceuticals provides update on Heparc-2004

* Notified verbally by United States FDA of its decision to place a clinical hold on heparc-2004

Nov 08 2016

BRIEF-Arrowhead Pharmaceuticals files for mixed shelf of up to $200 mln - SEC filing

* Files for mixed shelf of up to $200 million - SEC filing Source text: (http://bit.ly/2e5NfCw) Further company coverage:

Oct 28 2016

BRIEF-Arrowhead Pharma files for sale of aggregate of 3 mln shares of co's common stock by selling shareholder Amgen

* Arrowhead Pharmaceuticals Inc - Files for sale of aggregate of 3.0 million shares of co's common stock by selling shareholder Amgen Inc - SEC filing

Oct 28 2016

BRIEF-Arrowhead and Spring Bank report clinical collaboration

* Arrowhead And Spring Bank Announce Clinical Collaboration For Arc-520 and SB 9200 in chronic hepatitis B

Oct 06 2016

Amgen, Arrowhead team up on gene-therapies for heart disease

Amgen Inc said on Thursday it would buy a stake in Arrowhead Pharmaceuticals Inc and collaborate with the company to develop gene-silencing therapies for heart disease.

Sep 29 2016

UPDATE 1-Amgen, Arrowhead team up on gene-therapies for heart disease

Sept 29 Amgen Inc said on Thursday it would buy a stake in Arrowhead Pharmaceuticals Inc and collaborate with the company to develop gene-silencing therapies for heart disease.

Sep 29 2016

Earnings vs. Estimates